Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis

Journal of Rheumatology

Volumn 26, Issue 10, 1999, Pages 2173-2178

  Vayssairat, Michel ^a  

^a HÔPITAL TENON   (France)

Author keywords

Digital necrosis; Prostacyclin; Systemic sclerosis; Therapeutic

Indexed keywords

BERAPROST;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FINGER; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NECROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; EPOPROSTENOL; FEMALE; FINGERS; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; NECROSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; ULCER;

EID: 0032876554     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975;4:351-8.
2. Yardumian DA, Isenberg DA, Rustin M, et al. Successful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988;27:220-6.
3. McHugh NJ, Csuka M, Watson H, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43-7.
4. Wigley FM, Siebold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
5. Wigley FM, Wise RA, Siebold JR, et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis; a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
6. Belch JJF, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 1995;54:197-200.
7. Black CM, Halkier-Sorensen L, Belch JJF, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre placebo-controlled, dose-comparison study. Br J Rheumatol 1998;37:952-60.
8. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
9. Granier F, Vayssairat M, Priollet P, Housset E. Nailfold capillary microscopy in mixed connective tissue disease. Comparison with systemic sclerosis and systemic lupus erythematosus. Arthritis Rheum 1986;29:189-95.
10. Vayssairat M, Baudot N, Abuaf N, Johanet C. Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations. Clin Rheumatol 1992;11:356-63.
11. Greaves M, Malia RG, Milford Ward A, et al. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br J Rheumatol 1988;27:281-5.
12. Herrick AL, Illingworth K, Blann A, Hay CRM, Mollis S, Jayson MIV. von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122-7.
13. Belch JJF, Newman P, Drury JK, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet 1983;1:313-5.
14. Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. Arthritis Rheum 1998;41:670-7.
15. Vayssairat M, and the French Microcirculation Society Multicenter Group for the study of Vascular Acrosyndromes. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. J Rheumatol 1996;23:1917-20.
16. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989;298:561-4.
17. Torley HI, Madhok R, Capell HA, et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800-4.
18. Lau CS, Belch R, Madhok R, et al. A randomized, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Clin Exp Rheumatol 1993;11:35-40.
19. Kaburaki J, Kuwana M, Akizuki M, Takano M, Tojo T. Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis. Nippon Rhinsho 1995;18:29-35.
20. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992;35:688-93.
21. Arpaia G, Cimminiello C, Sardina M, et al. Microcirculatory effects of iloprost in patients with suspected secondary Raynaud's phenomenon. Vasc Surg 1995;29:37-42.
22. Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R. Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 1997;15:135-41.
23. Kanaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981;94:482-4.
24. Mannucci PM, Lombardi R, Lattuada A, Perticucci E, Valsecchi R, Remuzzi G. Supranormal von Willebrand factor multimers in scleroderma. Blood 1989;73:1586-91.
25. Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcircul Clin Exp 1992;11:375-82.
26. Blann AD, Sheeran TP, Emery P. von Willebrand factor: increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. Br J Biomed Sci 1997;54:5-9.
27. Friedman R, Mears GJ, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96:2782-4.